CHEK2, MGMT, SULT1E1 and SULT1A1 Polymorphisms and Endometrial Cancer Risk

Several single nucleotide polymorphisms (SNPs) in candidate genes of DNA repair and hormone pathways have been reported to be associated with endometrial cancer risk. We sought to confirm these associations in two endometrial cancer case-control sample sets and used additional data from an existing genome-wide association study to prioritize an additional SNP for further study. Five SNPs from the CHEK2, MGMT, SULT1E1 and SULT1A1 genes, genotyped in a total of 1597 cases and 1507 controls from two case-control studies, the Australian National Endometrial Cancer Study and the Polish Endometrial Cancer Study, were assessed for association with endometrial cancer risk using logistic regression analysis. Imputed data was drawn for CHEK2 rs8135424 for 666 cases from the Study of Epidemiology and Risk factors in Cancer Heredity study and 5190 controls from the Wellcome Trust Case Control Consortium. We observed no association between SNPs in the MGMT, SULT1E1 and SULT1A1 genes and endometrial cancer risk. The A allele of the rs8135424 CHEK2 SNP was associated with decreased risk of endometrial cancer (adjusted per-allele OR 0.83; 95%CI 0.70-0.98; p = .03) however this finding was opposite to that previously published. Imputed data for CHEK2 rs8135424 supported the direction of effect reported in this study (OR 0.85; 95% CI 0.65–1.10). Previously reported endometrial cancer risk associations with SNPs from in genes involved in estrogen metabolism and DNA repair were not replicated in our larger study population. This study highlights the need for replication of candidate gene SNP studies using large sample groups, to confirm risk associations and better prioritize downstream studies to assess the causal relationship between genetic variants and cancer risk. Our findings suggest that the CHEK2 SNP rs8135424 be prioritized for further study as a genetic factor associated with risk of endometrial cancer.

[1]  G. Abecasis,et al.  Genotype imputation. , 2009, Annual review of genomics and human genetics.

[2]  M. García-Closas,et al.  Two Estrogen-Related Variants in CYP19A1 and Endometrial Cancer Risk: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium , 2009, Cancer Epidemiology Biomarkers & Prevention.

[3]  Jiali Han,et al.  Polymorphisms in O6-methylguanine DNA methyltransferase and endometrial cancer risk. , 2006, Carcinogenesis.

[4]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[5]  T. Rebbeck,et al.  Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. , 2006, Journal of the National Cancer Institute.

[6]  Yurii S. Aulchenko,et al.  ProbABEL package for genome-wide association analysis of imputed data , 2010, BMC Bioinformatics.

[7]  S. Chanock,et al.  Genetic variation in CYP17 and endometrial cancer risk , 2008, Human Genetics.

[8]  Yurii S. Aulchenko,et al.  BIOINFORMATICS APPLICATIONS NOTE doi:10.1093/bioinformatics/btm108 Genetics and population analysis GenABEL: an R library for genome-wide association analysis , 2022 .

[9]  M. Beckmann,et al.  Genome-wide association study identifies a common variant associated with risk of endometrial cancer , 2011, Nature Genetics.

[10]  P. Hall,et al.  Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. , 2007, Human molecular genetics.

[11]  No Association between FTO or HHEX and Endometrial Cancer Risk , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[12]  M. García-Closas,et al.  The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in Non-Hispanic White Women , 2011, PloS one.

[13]  K. Czene,et al.  Progesterone receptor gene variants and risk of endometrial cancer. , 2011, Carcinogenesis.

[14]  K. Hemminki,et al.  Endometrial cancer: population attributable risks from reproductive, familial and socioeconomic factors. , 2005, European journal of cancer.